Here is a puzzle that has nagged metabolism researchers for years: two obesity drugs hit the same receptor in completely opposite ways, and patients lose weight either way. A mouse study out of Cambridge has now supplied an answer, and it is not that one drug wins the tug-of-war. The two classes were never competing for the same target — they operate in different parts of the brain.
The work comes from the Institute of Metabolic Science at the University of Cambridge and appears in Nature Metabolism. Switching the receptor on in the brainstem suppressed appetite. Switching that same receptor off in the hypothalamus also brought weight down, by an entirely separate route.
The receptor that works both ways
First, why any of this was confusing. A newer generation of weight loss drugs works by acting on receptors linked to appetite, cutting food intake, driving weight loss and helping regulate blood sugar.
The two household names, Wegovy and Ozempic, activate the glucagon-like peptide 1 receptor, better known as GLP-1R. Simple enough so far.
Then a second target enters the picture: the glucose-dependent insulinotropic polypeptide receptor, or GIPR. Mounjaro and Zepbound switch it on. MariTide shuts it down. The pharmacology points in opposite directions, the receptor is the same, and either route can promote weight loss.
For anyone trying to design the next drug, that is a genuine obstacle. When the mechanism is unclear, improving on it is guesswork.
How they pinned down the brain regions
The Cambridge researchers tackled the question with genetically engineered mice. In one group, GIPR was stripped from the brainstem — the region sitting at the base of the brain just above the spinal cord, which handles appetite and nausea. In a second group, the receptor was removed from the hypothalamus, which governs hunger and body weight. A third group of normal mice served as controls.
The animals then received various combinations: a GIPR agonist to switch the receptor on, a GIPR antagonist to block it, and a GLP-1 drug. The team measured food consumption, body weight, fat mass, blood sugar control and brain activity.
Lining up the three groups revealed where each drug was actually doing its work. Delete the receptor in one region, see which treatment stops having an effect, and the address falls out.
Agonists, it emerged, work through the brainstem. Turn GIPR on there and appetite falls, with body weight following.
The brake on your sense of fullness
Antagonists travelled a completely different path. Blocking GIPR produced weight loss via the hypothalamus rather than the brainstem.
This next detail is the one worth pausing over. Within the hypothalamus, GIPR appears to function as a sort of ‘brake’ on how forcefully the brainstem responds to signals that the body has had enough. Block the receptor, lift the brake, and those fullness signals land with more force.
One drug class, then, dampens appetite directly. The other prevents the brain from muting the message that you are full. A single receptor, two unrelated jobs, decided by the neighbourhood it sits in.
There were also indications that blocking GIPR could amplify drugs targeting the amylin receptor, a class still in its early days. That suggests GIPR antagonists may end up boosting several categories of obesity treatment rather than a single one.
What this means for MariTide and combination drugs
MariTide stands to gain most directly. Currently in phase 3 clinical trials, it combines GIPR antagonism with GLP-1 receptor agonism, and the Cambridge findings go some way toward explaining why that combination does anything in the first place.
Once the separate pathways are charted, combinations can be engineered deliberately rather than stumbled upon.
Dr. Jo Lewis, the study’s first author from the Institute of Metabolic Science at the University of Cambridge, said: “Understanding which brain circuits respond to these medications – and how they do so – could help us design better drugs that produce more weight loss with fewer side effects, and which might work in combination with other obesity medicines to even greater effect.”
Lewis said: “Our work also strengthens the idea that the brain is central to obesity treatment. Obesity drugs are not acting simply on the gut or pancreas. Instead, they have important effects on specific, identifiable brain circuits that regulate appetite and food intake.”
The caveat that matters
The caveat: this was done in mice. No one has demonstrated that these circuits operate the same way in humans, and the results may help scientists build better treatments rather than having already delivered them.
The urgency, though, follows from the size of the problem. Obesity affects more than a billion people worldwide and increases the risk of type 2 diabetes, cardiovascular disease and cancer. Losing weight can reduce part of that risk, though achieving it through diet and exercise alone is difficult.
Funding for the research came from the Medical Research Council and Wellcome.
For anyone following the field, the next single-target drug is not the story. The question is whether a brainstem-acting agonist and a hypothalamus-acting antagonist can be stacked without the side effects stacking up alongside them.
